Mark H. Kaplan

Mark H. Kaplan

Auto-generated profile, based on publicly available information

Mark H. Kaplan

Department of Microbiology and Immunology, Indiana University School of Medicine , Indianapolis, IN

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1996 in Immunity
Verified
Journal Article
Closed access
MKMark H Kaplan
Mark H Kaplan
USUlrike Schindler
Ulrike Schindler
SSStephen T Smiley
Stephen T Smiley
MGMichael J Grusby
Michael J Grusby

1 July 1996 in Nature
Verified
Journal Article
Closed access
MKMark H. Kaplan
Mark H. Kaplan
YSYa-Lin Sun
Ya-Lin Sun
THTimothy Hoey
Timothy Hoey
MGMichael J. Grusby
Michael J. Grusby

2 May 2010 in Nature Immunology
Verified
Journal Article
Open access
PDF file
HCHua-Chen Chang
Hua-Chen Chang
SSSarita Sehra
Sarita Sehra
RGRitobrata Goswami
Ritobrata Goswami
WYWeiguo Yao
Weiguo Yao
QYQing Yu
Qing Yu
MKMark H Kaplan
Mark H Kaplan
Interleukin 9 secretion contributes to allergic inflammation. Kaplan and colleagues identify the transcription factor PU.1 as being necessary for TH9 differentiation and as a contributing factor in allergic airway inflammation. CD4+ helper T cells acquire effector phenotypes that promote specialized inflammatory responses. We show that the ETS-family transcription factor PU.1 was required for the development of an interleukin 9 (IL-9)-secreting subset of helper T cells. Decreasing PU.1 expression either by conditional deletion in mouse T cells or the use of small interfering RNA in human T cells impaired IL-9 production, whereas ectopic PU.1 expression promoted IL-9 production. Mice with PU.1-deficient T cells developed normal T helper type 2 (TH2) responses in vivo but showed attenuated allergic pulmonary inflammation that corresponded to lower expression of Il9 and chemokines in peripheral T cells and in lungs than that of wild-type mice. Together our data suggest a critical role for PU.1 in generating the IL-9-producing (TH9) phenotype and in the development of allergic inflammation.

27 March 2011 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
SGShreevrat Goenka
Shreevrat Goenka
MKMark H. Kaplan
Mark H. Kaplan

28 October 2022 in Science Immunology
Verified
Journal Article
Open access
Jinyi TangJinyi Tang
Jinyi Tang
CZCong Zeng
Cong Zeng
TCThomas M. Cox
Thomas M. Cox
CLChaofan Li
Chaofan Li
YSYoung Min Son
Young Min Son
JSJie Sun
Jie Sun
SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the circulation; however, it is currently unknown whether it elicits effective immune responses in the respiratory tract, particularly against variants of concern (VOCs), including Omicron. We compared the SARS-CoV-2 S–specific total and neutralizing antibody responses, and B and T cell immunity, in the bronchoalveolar lavage fluid (BAL) and blood of COVID-19–vaccinated individuals and hospitalized patients. Vaccinated individuals had significantly lower levels of neutralizing antibody against D614G, Delta (B.1.617.2), and Omicron BA.1.1 in the BAL compared with COVID-19 convalescents despite robust S-specific antibody responses in the blood. Furthermore, mRNA vaccination induced circulating S-specific B and T cell immunity, but in contrast to COVID-19 convalescents, these responses were absent in the BAL of vaccinated individuals. Using a mouse immunization model, we demonstrated that systemic mRNA vaccination alone induced weak respiratory mucosal neutralizing antibody responses, especially against SARS-CoV-2 Omicron BA.1.1 in mice; however, a combination of systemic mRNA vaccination plus mucosal adenovirus-S immunization induced strong neutralizing antibody responses not only against the ancestral virus but also the Omicron BA.1.1 variant. Together, our study supports the contention that the current COVID-19 vaccines are highly effective against severe disease development, likely through recruiting circulating B and T cell responses during reinfection, but offer limited protection against breakthrough infection, especially by the Omicron sublineage. Hence, mucosal booster vaccination is needed to establish robust sterilizing immunity in the respiratory tract against SARS-CoV-2, including infection by the Omicron sublineage and future VOCs.

7 April 2015 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
MKMark H. Kaplan
Mark H. Kaplan
MHMatthew M. Hufford
Matthew M. Hufford
MOMatthew R. Olson
Matthew R. Olson